MorphoSys AG Reports First Quarter 2024 Financial Results :

MorphoSys AG reports results for the first quarter of 2024.


"The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first half of 2024. The acceptance period for the acquisition is currently...

Related Keywords

Canada , Germany , Boston , Massachusetts , United States , Planegg , Bayern , Austria , American , German , America , Jean Paul Kress , Monjuvi Minjuvi , Share Of Loss Associates , Constellation Pharmaceuticals Inc , Xencor Inc , Incyte Corporation , Development Rd Expenses , Novartis , American Society Of Clinical Oncology , Twitter , Linkedin , Morphosys Group Key Figures , Drug Administration , Group Revenues , Additional Group , Lymphoma Society , Exchange Commission , Company Annual Report On Form , European Medicines Agency , Nasdaq , German Federal Financial Supervisory Authority The Bafin , First Quarter , Management Board , Supervisory Board , Chief Executive Officer , Public Takeover Offer Highlights , Novartis Bidco , Morphosys Management Board , Conferences Highlights , Clinical Oncology , Net Loss , Discontinued Operations , New Drug Application , Marketing Authorization Application , Sys Group Key Figures , Impairment Losses , Financial Assets , Equity Method , Tax Benefit , Net Profit , Continued Operations , Investor Relations , Morphosys Investor Relations , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Prescribing Information , German Federal Financial Supervisory Authority , American Depositary Shares , Tender Offer Statement , Takeover Offer , Takeover Offer Documents , German Securities Acquisition , Takeover Act , Recommendation Statement , Recommendation Statements , Annual Report ,